



Humanigen

## THE CYTOKINE STORM COMPANY

Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms.

Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.

### PRODUCT PIPELINE

- **Lenzilumab™** (LENZ) is currently in a late-stage, rapidly-enrolling, 300 patient **Phase 3 clinical trial** for treatment of hospitalized patients with severe and critical **COVID-19** at high risk of progression
- **LENZ was selected by NIAID** for a fully **NIH-sponsored 200 patient clinical trial** in combination with Remdesivir for COVID-19
- **LENZ demonstrated positive results** in a case-control study published by **Mayo Clinic**
- Additional potential registrational trials are ongoing in **diffuse large B-cell lymphoma** (DLBCL) in collaboration with Kite Pharma/Gilead Sciences and other potential registrational trials are in late-stage planning in **acute GvHD and CMML**
- Potential to **improve efficacy of CAR-T therapies** while reducing serious and potentially life-threatening side effects
- An additional Phase 2 trial has been completed **evaluating LENZ in eosinophilic asthma**, and the company is seeking a development partner for a Phase 3 trial

Two other pipeline candidates are currently in development for solid tumors, inadequately controlled asthma and other eosinophilic diseases.

- **Ifabotuzumab:** anti-EphA3 monoclonal antibody currently being evaluated in solid tumors
- **HGEN005:** anti-EMR1 monoclonal antibody to be evaluated in severe eosinophilic diseases

### PARTNERSHIPS

- Clinical collaboration with Kite Pharma, a Gilead Company, in CAR-T
- Clinical Trial Agreement with NIAID in COVID-19
- Exclusive worldwide license agreement with the University of Zurich in GvHD
- Worldwide license agreement with the Mayo Foundation for Medical Education and Research in CAR-T
- Clinical Trial Agreement with IMPACT Group for aGvHD

## TEAM

Humanigen, Inc. is led by a senior management team with extensive leadership experience in the biotechnology and pharmaceutical industries.

### **Chairman & CEO**

Cameron Durrant, MD, MBA

### **Chief Scientific Officer**

Dale Chappell, MD, MBA

### **Chief Operating Officer & Chief Financial Officer**

Timothy Morris, CPA

### **Chief Accounting & Administrative Officer**

David Tousley, MBA, CPA

### **Head of Asia-Pacific Region**

Bob Atwill, MBA

### **Sr. Vice President, Clinical, Medical & Scientific Affairs**

Omar Ahmed, PharmD

## CONTACT

Humanigen, Inc.  
533 Airport Blvd #400  
Burlingame, CA 94010, USA  
650-243-3100

[humanigen@westwicke.com](mailto:humanigen@westwicke.com)

Twitter: [@humanigen](https://twitter.com/humanigen)

Learn more at <https://www.humanigen.com>

